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The basic helix-loop-helix transcription factor, NEUROG3, is critical in causing endocrine commitment from a
progenitor cell population in the developing pancreas. In human, NEUROG3 has been detected from 8 weeks post-
conception (wpc). However, the proﬁle of its production and when it ceases to be detected is unknown. In this study we
have deﬁned the proﬁle of NEUROG3 detection in the developing pancreas to give insight into when NEUROG3-
dependent endocrine commitment is possible in the human fetus. Immunohistochemistry allowed counting of cells
with positively stained nuclei from 7 wpc through to term. mRNA was also isolated from sections of human fetal
pancreas and NEUROG3 transcription analyzed by quantitative reverse transcription and polymerase chain reaction.
NEUROG3 was detected as expected at 8 wpc. The number of NEUROG3-positive cells increased to peak levels between
10 wpc and 14 wpc. It declined at and after 18 wpc such that it was not detected in human fetal pancreas at 35–41 wpc.
Analysis of NEUROG3 transcription corroborated this proﬁle by demonstrating very low levels of transcript at 35–41
wpc, more than 10-fold lower than levels at 12–16 wpc. These data deﬁne the appearance, peak and subsequent
disappearance of the critical transcription factor, NEUROG3, in human fetal pancreas for the ﬁrst time. By inference, the
window for pancreatic endocrine differentiation via NEUROG3 action opens at 8 wpc and closes between 21 and 35
wpc.
Introduction
Understanding b-cell differentiation is central to appreciating
how b-cell mass is generated in preparation for post-natal life.
This early step is especially pertinent as postnatal b-cell prolifera-
tion is highly restricted in human compared to rodent.1,2
Studies predominantly in mouse have demonstrated conclu-
sively that the basic helix-loop-helix (bHLH) factor, Neurogenin
3 (NEUROG3, also known as NGN3), is required for endocrine
commitment.3,4 This occurs in a population of progenitor cells
themselves regulated by key transcription factors, such as Sex
determining region Y-box 9 (SOX9) and pancreas and duodenal
homeobox 1 (PDX1).3,4 In mouse development, Neurog3 is
detectable in 2 phases from embryonic day (e) 8.5 to e11 and
during so-called ‘secondary transition’ from »e12 to e18, peak-
ing at e15.5,6 In human, there is evidence that the transcription
factor is required for endocrine cell differentiation; among several
reported cases, a severely inactivating mutation in NEUROG3
caused permanent neonatal diabetes with hyperglycemia the day
after birth and extreme loss of pro-endocrine function in in vitro
and in vivo assays.7 In early human embryos there is no first phase
of NEUROG3 but the transcription factor becomes progressively
detected immediately after the embryonic period at »8 weeks
post-conception timed with the appearance of the first fetal
b-cells.8 NEUROG3 has been reported in the human fetal pan-
creas until mid-gestation.9-11 However, the relative profile of its
expression, such as when its detection peaks, has been unclear;
and it is unknown whether and, if so, when NEUROG3 ceases
to be detected during human pre-natal development. Here, we
have studied a series of human fetuses to provide more complete
knowledge of when NEUROG3-dependent endocrine commit-
ment is possible during human gestation.
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Results
We counted cells showing NEUROG3 immunoreactivity in
specimens from Carnegie Stage 20 (47–50 dpc) until term. Aci-
nar differentiation has commenced prior to the first detection of
NEUROG3 immunoreactivity8 and is the cell lineage most
responsible for increasing pancreatic size during development.
Therefore, we quantified NEUROG3 detection both as a per-
centage of total pancreatic cells and as a percentage of the SOX9-
positive progenitor cell population. NEUROG3 was absent
<8 wpc but became progressively more apparent later in the first
trimester (Figs. 1A-B and 2A-B). Whether compared to either
total pancreatic cells or the SOX9-positive cell population, the
profile of NEUROG3 detection was very similar (Fig. 2A-B).
The highest prevalence of NEUROG3-positive cells as a propor-
tion of total epithelial cells occurred between 10 wpc and 14
wpc. When expressed as a proportion of the SOX9-positive pop-
ulation (i.e., excluding differentiated acinar cells8), the highest
levels of detection extended from 10 wpc until 17 wpc (Figs. 1C
and 2A-B) when NEUROG3-positive nuclei were »3.5–4% of
the number of cells stained for SOX9. After this period, NEU-
ROG3 declined such that it was not detected in all 8 of the speci-
mens tested at or after 35 wpc (Figs. 1D-E and 2A-B). In all
specimens, nuclear immunoreactivity was detected for SOX9
(Fig. 1A and E insets) and other transcription factors (data not
shown) confirming satisfactory integrity of the specimens. We
Figure 1. Proﬁle of immunohistochemistry for NEUROG3 during human
development. (A–E) Brightﬁeld images show NEUROG3 in brown coun-
terstained with toluidine blue. Insets (A) and (E) show brown SOX9 stain-
ing in nearby sections from the same fetus. Arrowheads exemplify
positively stained cells. Scale bar represents 50 mm in all panels.
Figure 2. Quantiﬁcation of NEUROG3 by cell-counting and mRNA analy-
sis during human fetal development. (A) and (B) The NEUROG3 count
was quantiﬁed relative to the total pancreatic epithelial cell population
(A) and the SOX9-positive cell population (B). By either approach the
NEUROG3 count at 10-11 wpc and at 12–14 wpc were statistically greater
than at <8 wpc, 18–21 wpc and 35–41 wpc. When quantiﬁed relative to
the SOX9-positive cell population, 10-11 wpc, 12–14 wpc and 15–17 wpc
emerged as the period of peak NEUROG3 detection. In neither (A) nor
(B), was there a signiﬁcant difference between counts at 10–11, 12–14
and 15–17 wpc. *P < 0.05, **P < 0.01, ^P < 0.005, ^^P < 0.0001 by one-
way ANOVA with post-hoc Tukey’s test. The number of specimens in
each group (n) is shown in parentheses. (C). Relative NEUROG3 expres-
sion by qRT-PCR demonstrated higher levels in samples from 12–16 wpc
than at 35–41 wpc. *P < 0 .01 by 2-tailed unpaired Student’s t-test.
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did not detect NEUROG3 staining in human pancreas either
during the first postnatal year or in adulthood (data not shown).
We have previously demonstrated that NEUROG3 produc-
tion in progenitor cells is marked by the exclusion of both
PDX110 and SOX9,8 and that NEUROG3 could not be detected
in insulin-positive cells.10 Here, we also showed that cells con-
taining nuclear NEUROG3 were non-proliferative by virtue of
absent PCNA staining (Fig. 3A) and did not contain glucagon
(Fig. 3B). Very occasional NEUROG3-positive cells possessed
weak staining for somatostatin (arrowhead in Fig. 3C). The anti-
NEUROG3 antibody was raised against the mouse protein. In
addition to the pre-incubation control data shown previously,10
here we demonstrate loss of staining following pre-incubation
specifically with the in vitro transcribed and translated full length
human NEUROG3 protein (Fig. 3D-E). Finally, to corroborate
the protein data, we performed qRT-PCR. Sample exhaustion
precluded exactly mirroring the range of specimens used to detect
protein. However, we analyzed NEUROG3 expression during the
window period of its high detection (12–16 wpc) and once we
could no longer detect NEUROG3 immunostaining (35–41
wpc) (Fig. 2C). Concordant with the protein data there was a
>10-fold decline in NEUROG3 transcripts from 12–16 wpc to
very low levels near term when the protein was no longer
detected.
Discussion
Significant work has been reported in recent years on human
b-cell numbers, proliferation and apoptosis as integral factors in
postnatal b-cell mass.1,2 However, due to restricted access to
human fetal material, no data exist on whether endocrine differ-
entiation ceases during human development and, if so, when. In
mouse pancreas, Neurog3 is required for islet cell differentia-
tion.3,4 Studies have also shown Neurog3 to be required for the
maintenance of islet cell function in adult mice.12,13 An equiva-
lent role in endocrine differentiation seems highly likely in
human given the neonatal diabetes and undetectable glucagon
when NEUROG3 was severely inactivated.7 However, the rela-
tive levels and prevalence of NEUROG3 during human gestation
has not been examined. In this brief report, we wanted to delin-
eate the profile of NEUROG3 in the developing human pancreas
to define the window period when NEUROG3-dependent endo-
crine commitment is feasible and, specifically, whether this win-
dow closes during gestation. We chose to quantify NEUROG3-
positive cells in 2 ways, each with its advantages and drawbacks.
The most straightforward approach expressed stained cells rela-
tive to the total population of pancreatic epithelial cells
(Fig. 2A). However, as development proceeds beyond embryo-
genesis this approach includes differentiated acinar cells in the
denominator. As an alternative denominator the SOX9-positive
population excludes acinar cells by 14 wpc8 (Fig. 2B). However,
at later time points in development not all SOX9-positive cells
are likely to be progenitors capable of endocrine differentiation
as terminally differentiated adult duct cells also contain SOX9.10
By either approach the profile of NEUROG3 was very similar.
Our data at the onset of NEUROG3 detection were very simi-
lar to those previously published from our own group and
others8-11; and are consistent with data from mouse indicating
that production of Neurog3 almost entirely marks non-prolifer-
ative cells.3 NEUROG3 was absent prior to 8 wpc (in Jennings
et al, one specimen of the 3 studied prior to 8 wpc contained 2
positive cells8). By either counting method, the peak NEUROG3
detection included the period from 10 wpc to 14 wpc. At 15–17
wpc the NEUROG3-positive population remained at approxi-
mately 3.5–4% of the SOX9-positive population (Fig. 2B) but
was slightly lowered when expressed relative to the total pancre-
atic cell population, possibly due to an increase in acinar cells at
the start of the second trimester.14 By both counting methods,
NEUROG3 then declined implying that the window of NEU-
ROG3-dependent endocrine commitment during human gesta-
tion closes between 21 wpc and 35 wpc. Interestingly, a recent
study of human fetal pancreas obtained at 7–9 wpc and engrafted
into mouse muscle showed NEUROG3 immunoreactivity at 19
weeks post-engraftment but not at the next time point studied,
Figure 3. Immunoﬂuoresence for NEUROG3 in human fetal pancreas.
(A–E) Immunoﬂuorescence for NEUROG3 at 14 wpc. (A) Arrowheads
point to green PCNA-positive cells while arrows point to separate red
NEUROG3-positive cells. (B) and (C) Arrows point to hormone-negative
NEUROG3-positive cells. Arrowhead points to a very rare NEUROG3-posi-
tive cell with faint somatostatin (SS) staining. (D) and (E) Arrowheads
point to NEUROG3-positive nuclei visible in (D) but not (E) following pre-
incubation with full-length human NEUROG3 protein. Ampliﬁcation of
the red gain with DAPI counterstaining to investigate the loss of nuclear
staining has introduced some background cytoplasmic staining. Scale
bar represents 50 mm.
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37 weeks.15 While caution is needed in extrapolating from these
human xenografts to normal gestation, pooling our data would
narrow the end of endocrine commitment to between 26–28 wpc
(i.e. 7–9 wpc at transplantation C19 weeks incubation in vivo15)
and 35 wpc. Our data on NEUROG3 transcripts were supportive
of the cell-counting data: while tissue exhaustion meant that we
could not conduct identically timed analyses, NEUROG3 tran-
scripts were readily detected at or near the peak prevalence of
NEUROG3-positive cells but greatly diminished once protein
was no longer detected. Previously, we have reported a lack of
NEUROG3 in fetal b-cells 10 and here show the same for fetal
a-cells. However, somatostatin was weakly apparent in very occa-
sional NEUROG3-positive cells perhaps suggestive of very early
delta-cell differentiation following the production of NEU-
ROG3. Others have reported NEUROG3 in human adult
islets.12 We did not detect NEUROG3 at or after 35 wpc prena-
tally or postnatally. However, the sensitivity of our immunohis-
tochemistry does not preclude cells that were negative here
having lower levels of NEUROG3 protein.
In summary, these combined data demonstrate the profile of
NEUROG3 detection during human gestation for the first time.
Alongside the knowledge that Neurog3 is critical for mouse
endocrine commitment3,4 and severe mutation causes permanent
neonatal diabetes in human,7 the combined implication is that
NEUROG3-dependent endocrine differentiation in human is
maximal at 10–17 wpc. Our data also imply that NEUROG3-
dependent endocrine differentiation ceases at some point
between 21 and 35 wpc after which further increases in prenatal
b-cell mass would presumably be reliant upon the balance of
b-cell proliferation versus apoptosis.
Methods
Human tissue
Fetal control material was obtained as described previously
with informed consent and ethical approval8,10,16 or obtained
anonymously according to the code established by the Dutch
Federation of Medical Scientific Societies (http://www.federa.
org) for appropriate secondary use. Thus, specimens were
acquired from either social / voluntary termination of pregnancy
or from death not related to the pancreas.
Immunohistochemistry, immunofluorescence and cell
counting
Immunohistochemistry and immunofluorescence were per-
formed as described previously8,16 on 5 mm sections of pancreas
using the primary antibodies and conditions listed in Supplemen-
tary Table 1. Cell counting data are presented as mean § stan-
dard error of the NEUROG3-positive population either relative
to the total pancreatic cell population or as a percentage of the
SOX9-positive population. Quantification of positively stained
cells for NEUROG3 and SOX9 was from entire serial sections of
fetal pancreas at 2 different positions from 3 separate fetuses
within each age group (total n D 32).
Isolation of RNA, reverse transcription and quantitative
PCR
Total RNA was isolated from tissue sections using the Qiagen
RNeasy FFPE kit protocol according to the manufacturer’s
instructions. Reverse transcription (RT) and quantitative PCR
(qRT-PCR) were performed as described previously using the
DDCT method standardized to 2 housekeeping controls,
GAPDH and b-ACTIN. Primers are listed in Supplementary
Table 2.
Statistical analysis
Cell counting across different age groups was compared by
one-way ANOVA followed by Tukey’s post-hoc test. qRT-PCR
between 12–16 wpc and 35–41 wpc was compared by a 2-tailed
unpaired Student’s t-test.
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